Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

A degenerative brain ailment called Huntington's disease (HTD) causes irritable behavior, emotional distress, cognition, . It is also known as Huntington's chorea. Compared to men, women are more likely to get HTD. However, in India, if 3 to 5% of Europeans are affected, it is difficult to estimate the disease's prevalence. The full pathophysiological status, several molecular pathways, and pharmaceutical and non-pharmacological treatments for Huntington's disease are covered in this article. Google, PubMed, Scopus, Bentham, Elsevier, and other significant web resources were used to gather the scientific data. Moreover, this review article may serve as the foundation for future study, particularly on Huntington's illness.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882276317240111103545
2024-04-16
2025-01-31

  • From This Site

    /content/journals/nemj/10.2174/0102506882276317240111103545
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/5/1/NEMJ-5-E02506882276317.html?itemId=/content/journals/nemj/10.2174/0102506882276317240111103545&mimeType=html&fmt=ahah

References

  1. Available from: https://www.genome.gov
  2. FrankS. Treatment of Huntington’s disease.Neurotherapeutics201411115316010.1007/s13311‑013‑0244‑z24366610
     [Google Scholar]
  3. Purves, Dale.Sunderland, MassNeuroscience2012415
     [Google Scholar]
  4. BatesG.P. DorseyR. GusellaJ.F. HaydenM.R. KayC. LeavittB.R. NanceM. RossC.A. ScahillR.I. WetzelR. WildE.J. TabriziS.J. Huntington disease.Nat. Rev. Dis. Primers2015111500510.1038/nrdp.2015.527188817
     [Google Scholar]
  5. Ferri FredF. Ferri’s differential diagnosis: A practical guide to the differential diagnosis of symptoms, signs and clinical disorders2nd ed.Philadelphia. PAElsevier/Mosby2010
     [Google Scholar]
  6. Molecular Pathogenesis in HTDAvailable from: protein.bio.msu.ru Retrieved 8 November 2020
     [Google Scholar]
  7. DayaluP. AlbinR.L. Huntington disease.Neurol. Clin.201533110111410.1016/j.ncl.2014.09.00325432725
     [Google Scholar]
  8. DurrA. GargiuloM. FeingoldJ. The presymptomatic phase of Huntington disease.Rev. Neurol.20121681180680810.1016/j.neurol.2012.07.00322902173
     [Google Scholar]
  9. Available from: www.nhsinform.scot. [Assessed 19 Nov. 2022]
  10. KulshreshthaM. GuptaJ. Memory impairment with reference to alzheimer’s disease: An update.Int. J. Nutr. Pharmacol. Neurol. Dis.201773455310.4103/ijnpnd.ijnpnd_7_17
     [Google Scholar]
  11. ArlingtonV.A. Diagnostic and statistical manual of mental disorders.APA2013158639
     [Google Scholar]
  12. WagleA.C. WagleS.A. MarkováI.S. BerriosG.E. Psychiatric morbidity in HTD.Neurol. Psychiatry Brain Res.20008516
     [Google Scholar]
  13. CaronN.S. WrightG.E. HaydenM.R. AdamM.P. ArdingerH.H. PagonR.A. WallaceS.E. BeanL.J. StephensK. AmemiyaA. Huntington Disease.Gene ReviewsUniversity of Washington,Seattle2020
     [Google Scholar]
  14. Available from: www.ninds.nih.gov [ Assessed 19 Nov 2022].
  15. FerriF.F. Ferri’s differential diagnosis: A practical guide to the differential diagnosis of symptoms, signs, and clinical disorders2nd edPhiladelphia. PA. Elsevier/Mosby2010
     [Google Scholar]
  16. FrankS. Treatment of HTD.Neurotherapeutics201411115316010.1007/s13311‑013‑0244‑z
     [Google Scholar]
  17. KremerB. BatesG. HarperP. JonesL. Clinical neurology of HTD. HTD.3rd edOxfordOxford University Press20122853
     [Google Scholar]
  18. PurvesD. Neuroscience SunderlandMass.; B5th ed2012415
     [Google Scholar]
  19. de BartolomeisA. TomasettiC. IasevoliF. Update on the mechanism of action of aripiprazole: Translational insights into antipsychotic strategies beyond dopamine receptor antagonism.CNS Drugs201529977379910.1007/s40263‑015‑0278‑326346901
     [Google Scholar]
  20. HeC. QuX. CuiL. WangJ. KangJ.X. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid.Proc. Natl. Acad. Sci. USA200910627113701137510.1073/pnas.090483510619549874
     [Google Scholar]
  21. SimopoulosA.P. Omega-3 fatty acids in inflammation and autoimmune diseases.J. Am. Coll. Nutr.200221649550510.1080/07315724.2002.1071924812480795
     [Google Scholar]
  22. SuK.P. HuangS.Y. ChiuT.H. HuangK.C. HuangC.L. ChangH.C. ParianteC.M. Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial.J. Clin. Psychiatry200869464465110.4088/JCP.v69n041818370571
     [Google Scholar]
  23. NoaghiulS. HibbelnJ.R. Cross-national comparisons of seafood consumption and rates of bipolar disorders.Am. J. Psychiatry2003160122222222710.1176/appi.ajp.160.12.222214638594
     [Google Scholar]
  24. HibbelnJ.R. Depression, suicide and deficiencies of omega-3 essential fatty acids in modern diets.World Rev. Nutr. Diet.200899173010.1159/00019299219136836
     [Google Scholar]
  25. AdamsP.B. LawsonS. SanigorskiA. SinclairA.J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.Lipids1996311Part2Suppl.S157S16110.1007/BF026370698729112
     [Google Scholar]
  26. TiemeierH. van TuijlH.R. HofmanA. KiliaanA.J. BretelerM.M.B. Plasma fatty acid composition and depression are associated in the elderly: The rotterdam study.Am. J. Clin. Nutr.2003781404610.1093/ajcn/78.1.4012816769
     [Google Scholar]
  27. MaesM. SmithR. ChristopheA. CosynsP. DesnyderR. MeltzerH. Fatty acid composition in major depression: decreased ω3 fractions in cholesteryl esters and increased C20:4ω6C20:5ω3 ratio in cholesteryl esters and phospholipids.J. Affect. Disord.1996381354610.1016/0165‑0327(95)00092‑58735157
     [Google Scholar]
  28. EdwardsR. PeetM. ShayJ. HorrobinD. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients.J. Affect. Disord.1998482-314915510.1016/S0165‑0327(97)00166‑39543204
     [Google Scholar]
  29. PeetM. MurphyB. ShayJ. HorrobinD. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients.Biol. Psychiatry199843531531910.1016/S0006‑3223(97)00206‑09513745
     [Google Scholar]
  30. MamalakisG. TornaritisM. KafatosA. Depression and adipose essential polyunsaturated fatty acids.Prostaglandins Leukot. Essent. Fatty Acids200267531131810.1054/plef.2002.043512445491
     [Google Scholar]
  31. ConklinS.M. GianarosP.J. BrownS.M. YaoJ.K. HaririA.R. ManuckS.B. MuldoonM.F. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults.Neurosci. Lett.2007421320921210.1016/j.neulet.2007.04.08617574755
     [Google Scholar]
  32. FreemanM.P. HibbelnJ.R. WisnerK.L. DavisJ.M. MischoulonD. PeetM. KeckP.E.Jr MarangellL.B. RichardsonA.J. LakeJ. StollA.L. Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry.J. Clin. Psychiatry200667121954196710.4088/JCP.v67n121717194275
     [Google Scholar]
  33. FreemanM.P. Omega-3 fatty acids and perinatal depression: A review of the literature and recommendations for future research.Prostaglandins Leukot. Essent. Fatty Acids2006754-529129710.1016/j.plefa.2006.07.00716930971
     [Google Scholar]
  34. HaagM. Essential fatty acids and the brain.Can. J. Psychiatry200348319520310.1177/07067437030480030812728744
     [Google Scholar]
  35. RapoportS.I. BosettiF. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?Arch. Gen. Psychiatry200259759259610.1001/archpsyc.59.7.59212090811
     [Google Scholar]
  36. BabcockT.A. KurlandA. HeltonW.S. RahmanA. AnwarK.N. EspatN.J. Inhibition of activator protein-1 transcription factor activation by omega-3 fatty acid modulation of mitogen-activated protein kinase signaling kinases.JPEN J. Parenter. Enteral Nutr.200327317618010.1177/014860710302700317612757110
     [Google Scholar]
  37. NovakT.E. BabcockT.A. JhoD.H. HeltonW.S. EspatN.J. KappaB. NF-κB inhibition by ω-3 fatty acids modulates LPS-stimulated macrophage TNF-α transcription.Am. J. Physiol. Lung Cell. Mol. Physiol.20032841L84L8910.1152/ajplung.00077.200212388359
     [Google Scholar]
  38. YaoH.T. ChangY.W. LanS.J. ChenC.T. HsuJ.T.A. YehT.K. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.Life Sci.200679262432244010.1016/j.lfs.2006.08.01616978661
     [Google Scholar]
  39. AndradeC. Ketamine for depression, 2: Diagnostic and contextual indications.J. Clin. Psychiatry2017785e555e55810.4088/JCP.17f1162928570803
     [Google Scholar]
  40. AndradeC. Ketamine for depression 3: Does chirality matter.J. Clin. Psychiatry2017786e674e67710.4088/JCP.17f1168128682536
     [Google Scholar]
  41. GarayR.P. ZarateC.A.Jr CharpeaudT. CitromeL. CorrellC.U. HamegA. LlorcaP.M. Investigational drugs in recent clinical trials for treatment-resistant depression.Expert Rev. Neurother.201717659360910.1080/14737175.2017.128321728092469
     [Google Scholar]
  42. FrankS. Huntington Study Group/TETRA-HD Investigators Tetrabenazine as anti-chorea therapy in Huntington Disease: An open-label continuation study.BMC Neurol.2009916210.1186/1471‑2377‑9‑6220021666
     [Google Scholar]
  43. KenneyC. HunterC. DavidsonA. JankovicJ. Short-term effects of tetrabenazine on chorea associated with Huntington’s disease.Mov. Disord.2007221101310.1002/mds.2116117078062
     [Google Scholar]
  44. JankovicJ. BeachJ. Long-term effects of tetrabenazine in hyperkinetic movement disorders.Neurology199748235836210.1212/WNL.48.2.3589040721
     [Google Scholar]
  45. OndoW.G. TintnerR. ThomasM. JankovicJ. Tetrabenazine treatment for Huntington’s disease-associated chorea.Clin. Neuropharmacol.200225630030210.1097/00002826‑200211000‑0000312469001
     [Google Scholar]
  46. KollerW.C. TrimbleJ. The gait abnormality of Huntington’s disease.Neurology198535101450145410.1212/WNL.35.10.14503162109
     [Google Scholar]
  47. GirottiF. CarellaF. SciglianoG. GrassiM.P. SoliveriP. GiovanniniP. ParatiE. CaraceniT. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington’s disease.J. Neurol. Neurosurg. Psychiatry198447884885210.1136/jnnp.47.8.8486147393
     [Google Scholar]
  48. McArthurA.W. PollockM. SmidtN.A. Combined therapy with tetrabenazine and pimozide in Huntington’s chorea: Pilot study.N. Z. Med. J.197683558114116131917
     [Google Scholar]
  49. van VugtJ.P.P. SieslingS. VergeerM. van der VeldeE.A. RoosR A C. Clozapine versus placebo in Huntington’s disease: A double blind randomised comparative study.J. Neurol. Neurosurg. Psychiatry1997631353910.1136/jnnp.63.1.359221965
     [Google Scholar]
  50. BonuccelliU. CeravoloR. MaremmaniC. NutiA. RossiG. MuratorioA. Clozapine in Huntington’s chorea.Neurology199444582182310.1212/WNL.44.5.8218190281
     [Google Scholar]
  51. ValletteN. GosselinO. KahnJ.P. [Efficacy of clozapine in the course of Huntington chorea: Apropos of a clinical case].Encephale200127216917111407269
     [Google Scholar]
  52. ColosimoC. CassettaE. BentivoglioA.R. AlbaneseA. Clozapine in Huntington’s disease.Neurology19954551023.1102310.1212/WNL.45.5.10237746380
     [Google Scholar]
  53. BonelliR.M. MahnertF.A. NiederwieserG. Olanzapine for Huntington’s disease: An open label study.Clin. Neuropharmacol.200225526326510.1097/00002826‑200209000‑0000712410058
     [Google Scholar]
  54. BogelmanG. HirschmannS. ModaiI. Olanzapine and Huntington’s disease.J. Clin. Psychopharmacol.200121224524610.1097/00004714‑200104000‑0002311270928
     [Google Scholar]
  55. BonelliR.M. NiederwieserG. DiezJ. KöltringerP. Riluzole and olanzapine in Huntington’s disease.Eur. J. Neurol.20029218318410.1046/j.1468‑1331.2002.0354f.x11882065
     [Google Scholar]
  56. BonelliR.M. NiederwieserG. TriblG.G. KöltringerP. High-dose olanzapine in Huntington’s disease.Int. Clin. Psychopharmacol.2002172919310.1097/00004850‑200203000‑0000911890191
     [Google Scholar]
  57. DippleH.C. The use of olanzapine for movement disorder in Huntington’s disease: A first case report.J. Neurol. Neurosurg. Psychiatry199967112312410.1136/jnnp.67.1.12310454874
     [Google Scholar]
  58. EtchebehereE.C.S.C. LimaM.C.L. PassosW. MacielJ.A.Jr SantosA.O. RamosC.D. CamargoE. Brain SPECT imaging in Huntington’s disease before and after therapy with olanzapine: Case report.Arq. Neuropsiquiatr.1999573B86386610.1590/S0004‑282X199900050002110751925
     [Google Scholar]
  59. GroveV.E.Jr QuintanillaJ. DeVaneyG.T. Improvement of Huntington’s disease with olanzapine and valproate.N. Engl. J. Med.20003431397397410.1056/NEJM20000928343131611012330
     [Google Scholar]
  60. Jimenez-JimenezF.J. de ToledoM. Puerta’s I.Rev. Neurol.2002356524525[Olanzapine improves chorea in patients with HTD].
     [Google Scholar]
  61. LaksJ. RochaM. CapitãoC. DominguesR.C. LadeiaG. LimaM. EngelhardtE. Functional and motor response to low dose olanzapine in huntington’s disease: Case report.Arq. Neuropsiquiatr.20046241092109410.1590/S0004‑282X200400060003015608976
     [Google Scholar]
  62. BonelliR.M. MayrB.M. NiederwieserG. ReiseckerF. KapfhammerH.P. Ziprasidone in Huntington’s disease: The first case reports.J. Psychopharmacol.200317445946010.1177/026988110317400914870962
     [Google Scholar]
  63. BouchetteD. FaribaK.A. MarwahaR. Ziprasidone.Stat Pearls.Treasure Island, FLStatPearls Publishing2022
     [Google Scholar]
  64. BrusaL. OrlacchioA. MoschellaV. IaniC. BernardiG. MercuriN.B. Treatment of the symptoms of Huntington’s disease: Preliminary results comparing aripiprazole and tetrabenazine.Mov. Disord.200924112612910.1002/mds.2237619170197
     [Google Scholar]
  65. CiammolaA. SassoneJ. ColciagoC. MencacciN.E. PolettiB. CiarmielloA. SquitieriF. SilaniV. Aripiprazole in the treatment of Huntington’s disease: A case series.Neuropsychiatr. Dis. Treat.200951419557093
     [Google Scholar]
  66. ParsaM.A. SzigethyE. VociJ.M. MeltzerH.Y. Risperidone in treatment of choreoathetosis of Huntington’s disease.J. Clin. Psychopharmacol.199717213413510.1097/00004714‑199704000‑0002310950488
     [Google Scholar]
  67. DallocchioC. BuffaC. TinelliC. MazzarelloP. Effectiveness of risperidone in Huntington chorea patients.J. Clin. Psychopharmacol.199919110110310.1097/00004714‑199902000‑000209934953
     [Google Scholar]
  68. cNeilSE. Gibbons JR. CogburnM. RisperidoneStatPearls Treasure Island (FL)StatPearls Publishing2022
     [Google Scholar]
  69. BonelliR.M. NiederwieserG. Quetiapine in Huntington’s disease: A first case report.J. Neurol.200224981114111510.1007/s00415‑002‑0741‑112420714
     [Google Scholar]
  70. MaanJ.S. ErshadiM. KhanI. Quetiapine.Stat Pearls.Treasure Island, FLStatPearls Publishing2022
     [Google Scholar]
  71. Verhagen MetmanL. MorrisM.J. FarmerC. GillespieM. MosbyK. WuuJ. ChaseT.N. Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine.Neurology200259569469910.1212/WNL.59.5.69412221159
     [Google Scholar]
  72. LucettiC. Del DottoP. GambacciniG. amantadine improves chorea in HTD: An acute randomized, controlled study.Neurology200360121995199710.1212/01.WNL.0000068165.07883.6412821751
     [Google Scholar]
  73. HeckmannJ.M. LeggP. SklarD. amantadine improves chorea in HTD: An acute randomized controlled study.Neurology200463359759810.1212/WNL.63.3.59715304616
     [Google Scholar]
  74. O’SuilleabhainP. DeweyR.B.Jr A randomized trial of amantadine in Huntington disease.Arch. Neurol.200360799699810.1001/archneur.60.7.99612873857
     [Google Scholar]
  75. ChangC. RamphulK. Amantadine.Stat Pearls.Treasure Island, FLStatPearls Publishing2022
     [Google Scholar]
  76. OndoW.G. MejiaN.I. HunterC.B. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease.Parkinsonism Relat. Disord.200713745345410.1016/j.parkreldis.2006.08.00517046312
     [Google Scholar]
  77. JohnsonJ. KotermanskiS. Mechanism of action of memantine.Curr. Opin. Pharmacol.200661616710.1016/j.coph.2005.09.00716368266
     [Google Scholar]
  78. PuriB.K. LeavittB.R. HaydenM.R. RossC.A. RosenblattA. GreenamyreJ.T. HerschS. VaddadiK.S. SwordA. HorrobinD.F. MankuM. MurckH. Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial.Neurology200565228629210.1212/01.wnl.0000169025.09670.6d16043801
     [Google Scholar]
  79. Huntington Study Group TREND-HD Investigators Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study.Arch. Neurol.200865121582158919064745
     [Google Scholar]
  80. Wikipedia contributors. Ethyl eicosapentaenoic acid. The free encyclopaedia2022
     [Google Scholar]
  81. de TommasoM. DifruscoloO. SciruicchioV. SpecchioN. LivreaP. Two years’ follow-up of rivastigmine treatment in Huntington disease.Clin. Neuropharmacol.2007301434610.1097/01.wnf.0000240945.44370.f017272969
     [Google Scholar]
  82. MüllerT. Rivastigmine in the treatment of patients with Alzheimer’s disease.Neuropsychiatr. Dis. Treat.20073221121810.2147/nedt.2007.3.2.21119300554
     [Google Scholar]
  83. CuboE. ShannonK.M. TracyD. JaglinJ.A. BernardB.A. WuuJ. LeurgansS.E. Effect of donepezil on motor and cognitive function in Huntington disease.Neurology20066771268127110.1212/01.wnl.0000238106.10423.0017030764
     [Google Scholar]
  84. FernandezH.H. FriedmanJ.H. GraceJ. Beason-HazenS. Donepezil for Huntington’s disease.Mov. Disord.200015117317610.1002/1531‑8257(200001)15:1<173::AID‑MDS1032>3.0.CO;2‑T10634264
     [Google Scholar]
  85. CacabelosR. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics.Neuropsychiatr. Dis. Treat.20073330333319300564
     [Google Scholar]
  86. ComoP.G. RubinA.J. O’BrienC.F. LawlerK. HickeyC. RubinA.E. HendersonR. McDermottM.P. McDermottM. SteinbergK. ShoulsonI. A controlled trial of fluoxetine in nondepressed patients with Huntington’s disease.Mov. Disord.199712339740110.1002/mds.8701203199159735
     [Google Scholar]
  87. SohelA.J. ShutterM.C. MollaM. Fluoxetine.StatPearls.Treasure Island, FLStatPearls Publishing2022
     [Google Scholar]
  88. SinghD. SaadabadiA. Venlafaxine.Stat Pearls Treasure Island.FLStatPearls Publishing2022
     [Google Scholar]
  89. HollA.K. WilkinsonL. PainoldA. HollE.M. BonelliR.M. Combating depression in Huntingtonʼs disease: Effective antidepressive treatment with venlafaxine XR.Int. Clin. Psychopharmacol.2010251465010.1097/YIC.0b013e328334801819996754
     [Google Scholar]
  90. AnttilaS.A.K. LeinonenE.V.J. A review of the pharmacological and clinical profile of mirtazapine.CNS Drug Rev.20017324926410.1111/j.1527‑3458.2001.tb00198.x11607047
     [Google Scholar]
  91. BonelliR.M. Mirtazapine in suicidal Huntington’s disease.Ann. Pharmacother.200337345210.1345/aph.1C35212639181
     [Google Scholar]
  92. RanenN.G. LipseyJ.R. TreismanG. RossC.A. Sertraline in the treatment of severe aggressiveness in Huntington’s disease.J. Neuropsychiatry Clin. Neurosci.19968333834010.1176/jnp.8.3.3388854307
     [Google Scholar]
  93. SinghH.K. SaadabadiA. Sertraline.Stat Pearls Treasure Island.FLStatPearls Publishing2022
     [Google Scholar]
  94. BhandaryA.N. MasandP.S. Buspirone in the management of disruptive behaviours due to HTD and other neurological disorders.Psychosomatics199738438939110.1016/S0033‑3182(97)71447‑69217410
     [Google Scholar]
  95. ByrneA. MartinW. HnatkoG. Beneficial effects of buspirone therapy in Huntington’s disease.Am. J. Psychiatry199415171097a109710.1176/ajp.151.7.1097a8010374
     [Google Scholar]
  96. FindlingR.L. Treatment of aggression in juvenile-onset Huntington’s disease with buspirone.Psychosomatics199334546046110.1016/S0033‑3182(93)71857‑58140199
     [Google Scholar]
  97. JannM.W. Buspirone: An update on a unique anxiolytic agent.Pharmacotherapy19888210011610.1002/j.1875‑9114.1988.tb03543.x3041384
     [Google Scholar]
  98. Pan-InP. WongsomboonA. KokpolC. ChaichanawongsarojN. WanichwecharungruangS. Depositing α-mangostin nanoparticles to sebaceous gland area for acne treatment.J. Pharmacol. Sci.2015129422623210.1016/j.jphs.2015.11.00526701606
     [Google Scholar]
  99. ZhangH. PanN. XiongS. ZouS. LiH. XiaoL. CaoZ. TunnacliffeA. HuangZ. Inhibition of polyglutamine-mediated proteotoxicity by Astragalus membranaceus polysaccharide through the DAF-16/FOXO transcription factor in Caenorhabditis elegans.Biochem. J.2012441141742410.1042/BJ2011062121892924
     [Google Scholar]
  100. ChenC.C. HungT.H. LeeC.Y. WangL.F. WuC.H. KeC.H. ChenS.F. Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury.PLoS One2014912e11569410.1371/journal.pone.011569425546475
     [Google Scholar]
  101. ChoiB.S. KimH. LeeH.J. SapkotaK. ParkS.E. KimS. KimS.J. Celastrol from ‘Thunder God Vine’ protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson’s disease.Neurochem. Res.2014391849610.1007/s11064‑013‑1193‑y24214023
     [Google Scholar]
  102. NazR.K. LoughM.L. BarthelmessE.K. Curcumin a novel non-steroidal contraceptive with antimicrobial properties.Front. Biosci.20168111312810.2741/e75526709650
     [Google Scholar]
  103. Cheng-Chung WeiJ. HuangH.C. ChenW.J. HuangC.N. PengC.H. LinC.L. Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia.Eur. J. Pharmacol.2016770162410.1016/j.ejphar.2015.11.04826643169
     [Google Scholar]
  104. SajjadiS.E. ShokoohiniaY. MoayediN.S. Isolation and identification of ferulic acid from aerial Parts of Kelussia odoratissima Mozaff.Jundishapur J. Nat. Pharm. Prod.20127415916210.17795/jjnpp‑486124624175
     [Google Scholar]
  105. BerkovS. BastidaJ. SidjimovaB. ViladomatF. CodinaC. Alkaloid diversity in Galanthus elwesii and Galanthus nivalis.Chem. Biodivers.20118111513010.1002/cbdv.20090038021259423
     [Google Scholar]
  106. IvanovD.A. GeorgakopoulosJ.R.C. BernardsM.A. The chemoattractant potential of ginsenosides in the ginseng – Pythium irregulare pathosystem.Phytochemistry2016122566410.1016/j.phytochem.2015.11.00526608666
     [Google Scholar]
  107. AhmadiA. ShadboorestanA. NabaviS.F. SetzerW.N. NabaviS.M. The role of hesperidin in cell signal transduction pathway for the prevention or treatment of cancer.Curr. Med. Chem.201522303462347110.2174/09298673223015101910381026502950
     [Google Scholar]
  108. CooperstoneJ.L. RalstonR.A. RiedlK.M. HaufeT.C. SchweiggertR.M. KingS.A. TimmersC.D. FrancisD.M. LesinskiG.B. ClintonS.K. SchwartzS.J. Enhanced bioavailability of lycopene when consumed as cis ‐isomers from tangerine compared to red tomato juice, a randomized, cross‐over clinical trial.Mol. Nutr. Food Res.201559465866910.1002/mnfr.20140065825620547
     [Google Scholar]
  109. ChambersR.P. CallG.B. MeyerD. SmithJ. TechauJ.A. PearmanK. BuhlmanL.M. Nicotine increases lifespan and rescues olfactory and motor deficits in a Drosophila model of Parkinson’s disease.Behav. Brain Res.20132539510210.1016/j.bbr.2013.07.02023871228
     [Google Scholar]
  110. WuA.G. WongV. XuS.W. ChanW.K. NgC.I. LiuL. LawB. Onjisaponin B derived from radix polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells.Int. J. Mol. Sci.20131411226182264110.3390/ijms14112261824248062
     [Google Scholar]
  111. FrickerG. Drug interactions with natural products at the blood brain barrier.Curr. Drug Metab.20089101019102610.2174/13892000878692775819075618
     [Google Scholar]
  112. GiridharanV.V. ThandavarayanR.A. ArumugamS. MizunoM. NawaH. SuzukiK. KoK.M. KrishnamurthyP. WatanabeK KonishiT. GiridharanV.V. Schisandrin B ameliorates ICV-infused amyloid β induced oxidative stress and neuronal dysfunction through inhibiting RAGE/NF-κB/MAPK and up-regulating HSP/Beclin expression.PLoS One201510
     [Google Scholar]
  113. Sonia AngelineM. SarkarA. AnandK. AmbastaR.K. KumarP. Sesamol and naringenin reverse the effect of rotenone-induced PD rat model.Neuroscience201325437939410.1016/j.neuroscience.2013.09.02924070629
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882276317240111103545
Loading
Molecular Pathways and Treatment Updates on Huntington’s Disease with Special Preference to Juvenile Phase: A Comprehensive Review
NEW Emirates Medical J 5, e02506882276317 (2024); https://doi.org/10.2174/0102506882276317240111103545
/content/journals/nemj/10.2174/0102506882276317240111103545
/content/journals/nemj/10.2174/0102506882276317240111103545
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): Antidopaminergic agents; Antipsychotic agents; Chorea; Huntington’s disease; N-Methyl-D-aspartic acid receptor antagonists; Omega- 3 fatty acids

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test